Lunit INSIGHT MMG

by Lunit  · Based in South Korea → — Seamless AI Support for Breast Cancer Detection
Radiology
Website
Claim this tool
Is this the maker? Claim the company →

Contact vendor
Regulatory Status Disclosed

Overview

Lunit INSIGHT MMG is an AI-powered software designed to assist radiologists in the interpretation of 2D mammograms for earlier and more accurate breast cancer detection. It leverages deep learning technology to automatically detect suspicious areas such as masses, calcifications, distortions, and asymmetries. The software provides malignancy likelihood scores and visually highlights key areas of interest through heatmaps or contour maps, empowering radiologists with enhanced insights during image review.

Designed for streamlined integration with PACS and existing viewer systems, Lunit INSIGHT MMG supports both single- and double-reading workflows, aiming to shorten reading times, reduce cognitive load, and address the shortage of breast imaging specialists in high-volume settings. Clinical studies have demonstrated its ability to improve screening accuracy, especially in dense breasts, reduce false positives, and minimize unnecessary patient callbacks.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • AI-powered detection of suspicious areas (mass, calcification, distortion, asymmetry)
  • Malignancy likelihood scores and abnormality scores for lesions and breasts
  • Localization of suspicious areas using heatmaps, contour maps, or color/outline
  • Seamless PACS and viewer integration
  • Supports single- and double-reading workflows
  • Reduces reading time and cognitive load for radiologists
  • Improves screening accuracy, particularly in dense breasts
  • Reduces false positives and unnecessary patient callbacks
  • Provides an assessment of breast density (not FDA-cleared for this feature)
  • Supports DICOM GSPS, DICOM Secondary Capture, DICOM SR, and HL7 for data exchange

Use Cases

  • Earlier breast cancer detection in 2D mammograms
  • Assisting radiologists in interpreting complex mammography images
  • Reducing radiologist workload and addressing specialist shortages in high-volume settings
  • Improving diagnostic accuracy for women with dense breasts
  • Triage of normal cases to allow radiologists to focus on suspicious findings
  • Supporting decision-making for BI-RADS category 3 and 4 cases

What Physicians Need to Know

Key Capabilities
Lunit INSIGHT MMG is an AI-powered mammography solution that assists radiologists in detecting suspicious areas for breast cancer, including masses, calcifications, distortions, and asymmetry. It provides location information of detected lesions (heatmaps/contour maps) and abnormality scores indicating the likelihood of malignancy. The tool supports earlier diagnosis, especially in dense breasts and for interval cancers, and can help prioritize cases requiring immediate attention. It also offers automated breast density assessment based on BI-RADS.
Clinical Utility
Lunit INSIGHT MMG functions as a second reader, enhancing radiologists' decision-making with AI-powered insights. It aims to improve breast cancer screening accuracy, reduce false positive recalls, and minimize unnecessary callbacks. Studies suggest it can boost early-stage cancer detection rates by up to 15% and reduce radiologist workload by nearly 70% in a hybrid workflow scenario. It can also expedite diagnosis by an average of nearly 30 months compared to traditional methods.
Integration Options
The software is designed for seamless integration into existing PACS (Picture Archiving and Communication Systems) and viewer infrastructure. It supports streamlined workflows, including single- and double-reading, and can integrate with other Lunit INSIGHT solutions like Lunit INSIGHT DBT.
Compliance Status
Lunit INSIGHT MMG has received FDA 510(k) clearance in the US and CE Mark approval, and is approved for commercial sales in over 35 countries worldwide. It also has regulatory clearance in Canada, the UK, Australia, and New Zealand.
Pricing Model
The pricing model for Lunit INSIGHT MMG is not explicitly specified, but Lunit INSIGHT generally offers a freemium model with a free plan and trial available, and requires an account for registration.
User Experience
The tool is designed to reduce reading time, simplify image review by highlighting key areas of interest, and decrease cognitive load for radiologists. It aims to improve patient experience by reducing callbacks and anxiety through clearer and more consistent interpretations.
Support Quality
Lunit provides dedicated technical support and full program support, including training and marketing materials.
Implementation Complexity
The implementation process is described as structured and multi-phased to ensure accuracy, reliability, and minimal disruption, with seamless compatibility with existing IT systems.
Evidence Base
Lunit INSIGHT MMG is backed by extensive peer-reviewed research and retrospective studies, with over 95 independent studies across diverse clinical settings. It has been trained with a large dataset of over 240,000 mammography cases, including up to 50,000 breast cancer cases. Studies have shown it outperforms other commercialized AI solutions in breast cancer detection, improves accuracy in dense breasts, and can maintain or improve screening quality while reducing workload.
Physician Tip

Lunit INSIGHT MMG acts as a valuable second opinion, especially in challenging cases like dense breasts, potentially catching cancers that might otherwise be missed. It can significantly reduce your workload by triaging mammograms and highlighting suspicious areas, allowing you to focus on critical cases. The abnormality scores and heatmaps provide clear, actionable insights, but always integrate these with your clinical judgment and patient history. Leveraging this AI can lead to earlier diagnoses and fewer unnecessary recalls, improving patient outcomes and reducing anxiety.

Lunit INSIGHT MMG is designed for seamless integration with existing PACS and viewer systems, supporting both single and double-reading workflows. It can be part of a broader Lunit INSIGHT ecosystem, integrating with solutions like Lunit INSIGHT DBT for 3D mammography and other breast care tools for risk assessment and quality assurance.

Details

Category Oncology AI, Radiology & Imaging AI
Pricing Contact vendor
DeploymentSeamless integration into existing PACS and viewers; flexible deployment options.
Compliance
BAA Available Yes AI-estimated
HIPAA Compliant Yes AI-estimated
FDA Status Cleared AI-estimated
Integrations
EHR Not specified
Specialties Radiology

What the Web Says

Lunit INSIGHT MMG is an AI-powered mammography solution designed to assist radiologists in detecting breast cancer, often identifying subtle signs that might be missed by the human eye. It aims to improve screening accuracy, especially in dense breasts, and reduce radiologist workload by providing AI-driven insights during image review. Studies have shown its effectiveness in early cancer detection, including in cases that were initially overlooked.

Overall: Positive

Strengths

  • Improved breast cancer detection rates, including earlier diagnosis of small-sized tumors and node-negative cancers.
  • Reduced radiologist workload and reading time, with potential to cut workload by nearly 70% in some scenarios.
  • Higher accuracy in detecting cancer, particularly in dense breasts.
  • Reduced false positives and unnecessary callbacks, leading to less patient anxiety and follow-up burden.
  • Seamless integration with existing PACS and RIS systems.
  • Provides an abnormality score and heatmaps to highlight suspicious areas, aiding in case prioritization.

Limitations

  • Potential trust gap between human clinicians and AI tools, leading radiologists to recall fewer AI-flagged cases even when they are more likely to be cancerous.
  • Some users express skepticism about paying for an AI service when a doctor should already be providing a thorough check.
  • Concerns about the need for FDA review and approval for software updates that adjust algorithms or diagnostic functions.
  • Can be expensive for smaller clinics as it operates at an enterprise level.
  • More studies are needed to expand its role in double readings.
  • AI tools may have a more modest clinical impact on recall and biopsy rates than expected.

Based on reviews from: ai-review.com, capterra.com, capterra.ca, lunit.io, auntminnie.com, bioworld.com, maidenlanemedical.com, sectra.com, biospace.com, koreabiomed.com, nih.gov, youtube.com, prnewswire.com, medium.com, wordpress.com, reddit.com, blackfordanalysis.com, oecd.ai

Last updated: 2026-10-30

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate Lunit INSIGHT MMG

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

lunit.io
Lunit's AI Demonstrates Up to 70% Workload Reduction and Enhanced Accuracy in Breast Cancer Screening: Study in European Radiology Reveals
A study published in European Radiology highlighted Lunit INSIGHT MMG's effectiveness in reducing radiologists' workload by nearly 70% and boosting cancer detection accuracy by 30.5% through a hybrid workflow. The research, involving over 22,621 mammograms, also showed the AI system identified 51.72% of interval cancers and could expedite diagnosis by almost 30 months.
2024-04
lunit.io
Lunit Study in Radiology Highlights Trust Gap Between Radiologists and AI in Breast Cancer Screening
A study published in Radiology, based on the ScreenTrustCAD trial, revealed a trust gap between radiologists and AI in breast cancer screening, as radiologists were less likely to recall patients flagged by Lunit INSIGHT MMG even when those cases were more likely to be cancerous. The study, involving approximately 55,000 women, confirmed the AI's strong diagnostic performance, with 22% of AI-only flagged cases being diagnosed with cancer.
2025-04
lunit.io
From research to real-world impact: Lunit demonstrates Lunit INSIGHT's clinical safety, effectiveness, and efficiency in 100 papers
Lunit announced the publication of 100 peer-reviewed papers featuring its Lunit INSIGHT suite, including 45 on breast cancer with Lunit INSIGHT MMG. These studies, published in journals like The Lancet Digital Health and JAMA Oncology, provide substantial clinical evidence for the safety, effectiveness, and efficiency of Lunit INSIGHT products.
2024-05
appliedradiology.com
Studies Find Lunit AI Predicts Breast Cancer Risk up to Six Years in Advance, Reduces Radiologist Workload
Research published in JAMA Network Open indicated that Lunit INSIGHT MMG can estimate future breast cancer risk up to 4 to 6 years before detection. Another study demonstrated that using Lunit's AI could reduce radiologist reading volume by nearly 50% while maintaining or improving cancer detection accuracy.
2024-10
lunit.io
Lunit's AI Software for Breast Cancer Detection, Lunit INSIGHT MMG, Wins FDA Clearance
Lunit announced that its AI solution for breast cancer detection, Lunit INSIGHT MMG, received US FDA 510(k) clearance, making it commercially available across the United States. The product analyzes mammography images with high accuracy, providing lesion locations and abnormality scores, and has been trained with over 240,000 mammography cases.
2021-11
marketscreener.com
Lunit Expands Lunit Insight MMG as an Independent Second Reader Across the Entire Stockholm Region in Sweden
Lunit INSIGHT MMG will be implemented as an independent second reader across the Stockholm Region in Sweden, covering Capio Saint Göran Hospital, Karolinska University Hospital, and Södersjukhuset. This deployment, in collaboration with Sectra, is expected to support 200,000 to 250,000 examinations annually and builds on successful clinical validation and real-world use.
2026-09
auntminnie.com
Lunit highlights Insight MMG clinical results
A study published in Nature Communications validated Lunit INSIGHT MMG's effectiveness in South Korea's national breast cancer screening program, showing AI-assisted radiologists detected 13.8% more screen-detected breast cancers. The cancer detection rate increased from five to 5.7 per 1,000 with AI assistance, without statistically significant changes in recall rates.
2025-03
healthcareitnews.com
Lunit INSIGHT MMG Receives CE Mark
Lunit INSIGHT MMG received CE certification, making it commercially available across the European Economic Area. The AI solution analyzes mammography images with 97% accuracy, providing lesion locations and abnormality scores, and was first introduced at the 2018 RSNA annual meeting.
2020-06

Videos

Product demos, reviews, and walkthroughs for Lunit INSIGHT MMG.

View all on YouTube

Frequently Asked Questions

Lunit INSIGHT MMG is an AI-powered software designed to help radiologists detect breast cancer by analyzing mammograms. It identifies and classifies suspicious areas, such as masses, calcifications, distortions, and asymmetries, generating heatmaps and abnormality scores to indicate the likelihood of malignancy. This tool aims to improve diagnostic accuracy, especially in dense breasts, and can potentially reduce reading time for radiologists.
Lunit INSIGHT MMG is FDA-cleared and CE-marked, and has received approval from the Korean Ministry of Food and Drug Safety (MFDS). It is designed to integrate seamlessly with existing PACS and viewer systems, supporting standard DICOM formats. The software is independently validated to meet performance standards and prevent bias, and images from commercial sites are not used for retraining.
Lunit INSIGHT MMG is intended as an adjunctive tool to assist radiologists, not to replace their complete clinical review or judgment. However, studies have shown its potential to serve as an independent reader in a double-reading system, maintaining or even improving cancer detection rates while reducing radiologist workload. In some European settings, it has been implemented to replace one human reader in breast cancer screening.
While Lunit INSIGHT MMG shows strong performance, it is important to note that its assessment of breast density is not FDA-cleared. Additionally, some studies evaluating its performance have been retrospective, which may reduce their statistical weight compared to prospective randomized controlled trials. The AI also has limitations in identifying certain cancer subtypes, offering practical insight into its strengths and weaknesses.
Lunit INSIGHT MMG has demonstrated superior or comparable performance to human radiologists and other AI solutions in various studies. For instance, in collaboration with a single radiologist, it has shown a higher Cancer Detection Rate than the traditional two-radiologist approach. It has also outperformed other commercial AI algorithms in terms of accuracy and sensitivity in detecting malignant lesions.
Integrating Lunit INSIGHT MMG can lead to several benefits, including earlier breast cancer detection, especially in dense breasts and interval cancers. It can also help reduce false positives and unnecessary recalls, thereby lowering patient anxiety and the follow-up burden on clinical teams. Furthermore, it can shorten reading times and support both single and double-reading workflows, addressing the shortage of breast imaging specialists.
Lunit INSIGHT MMG was trained using a large-scale, high-quality dataset of over 200,000 to 240,000 mammography cases, including up to 50,000 biopsy-proven breast cancer cases. This diverse training data was sourced from various countries, including Korea, the United States, and the United Kingdom.

Related Tools

SOPHiA DDM
SOPHiA GENETICS
Oncology AI
SOPHiA DDM™ is an AI-driven and cloud-powered platform that helps clinicians generate real-time, actionable insights for patients with cancer and rare disorders by analyzing complex genomic, radiomic, and multimodal data.
Paid
CerviCARE AI
NTL Healthcare
OB/GYN AI
CerviCARE AI is an AI-powered cervical cancer screening system that analyzes smartphone images of the cervix to predict findings, aiming for early detection.
Lumonus AI
Lumonus
Clinical Decision Support & Reference
Lumonus AI is an AI-powered software that assists healthcare providers with prescriptions, dosing, and treatment for cancer patients, with a module (Sigma) that suggests treatment protocols based on prior plans for similar patients.
DeepBio DeepDx® Prostate
DeepBio
Oncology AI
DeepDx® Prostate leverages deep learning to standardize prostate cancer diagnostics by detecting abnormalities in digital slides with high precision, providing automated Gleason grading, tumor quantification, and tumor length measurements.
AIRA Matrix AI Solutions
AIRA Matrix
Lab & Diagnostics
AIRA Matrix offers AI solutions to improve efficiency and diagnostic accuracy in pathology lab workflows, primarily for prostate and breast cancer, with services like DPaaS and predictive toxicology.
Surgical Reality Viewer
Surgical Reality
Oncology AI
Surgical Reality offers CE- and FDA-certified AI-powered 3D medical imaging and surgical planning software that transforms CT scans into patient-specific 3D models for thoracic surgery, enhancing precision in complex lung procedures.

See all Oncology AI tools →

More from Lunit

Lunit INSIGHT CXR Triage
Lunit
Radiology & Imaging AI
Lunit INSIGHT CXR Triage is an FDA-cleared AI solution that analyzes chest X-ray images to identify and prioritize emergent cases of pleural effusion and pneumothorax, optimizing workflow in critical care settings.
Lunit INSIGHT DBT
Lunit
Oncology AI
Lunit INSIGHT DBT is an AI-powered software that enhances breast cancer detection in 3D digital breast tomosynthesis (DBT) exams, aiding radiologists with precise lesion identification, classification, and navigation to improve diagnostic accuracy and efficiency.

View company profile →

Suggest an Edit → | Report an issue | Last Verified: 2026-04-18 | First Added: 2026-04-18

Investors who backed Lunit INSIGHT MMG

Funded through the company that built this tool.

Mirae Asset Venture Investments
Corporate VC T2
Seoul, South Korea
$5M-$25M
Mirae Asset Venture Investments is the venture capital arm of Mirae Asset Financial Group, a major South Korean financial services firm. The…
Digital Health
AI Tool Finder
AI-powered search. Results may not be comprehensive.